Hieronymus W. H. van Hees
Radboud University Nijmegen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hieronymus W. H. van Hees.
American Journal of Respiratory and Critical Care Medicine | 2015
Pleuni E. Hooijman; Albertus Beishuizen; Christian Witt; Monique C. de Waard; Armand R. J. Girbes; Angelique M. E. Spoelstra-de Man; Hans W.M. Niessen; Emmy Manders; Hieronymus W. H. van Hees; Charissa E. van den Brom; Vera Silderhuis; Michael W. Lawlor; Siegfried Labeit; Ger J.M. Stienen; Koen J. Hartemink; Marinus A. Paul; Leo M. A. Heunks; Coen A.C. Ottenheijm
RATIONALE The clinical significance of diaphragm weakness in critically ill patients is evident: it prolongs ventilator dependency, and increases morbidity and duration of hospital stay. To date, the nature of diaphragm weakness and its underlying pathophysiologic mechanisms are poorly understood. OBJECTIVES We hypothesized that diaphragm muscle fibers of mechanically ventilated critically ill patients display atrophy and contractile weakness, and that the ubiquitin-proteasome pathway is activated in the diaphragm. METHODS We obtained diaphragm muscle biopsies from 22 critically ill patients who received mechanical ventilation before surgery and compared these with biopsies obtained from patients during thoracic surgery for resection of a suspected early lung malignancy (control subjects). In a proof-of-concept study in a muscle-specific ring finger protein-1 (MuRF-1) knockout mouse model, we evaluated the role of the ubiquitin-proteasome pathway in the development of contractile weakness during mechanical ventilation. MEASUREMENTS AND MAIN RESULTS Both slow- and fast-twitch diaphragm muscle fibers of critically ill patients had approximately 25% smaller cross-sectional area, and had contractile force reduced by half or more. Markers of the ubiquitin-proteasome pathway were significantly up-regulated in the diaphragm of critically ill patients. Finally, MuRF-1 knockout mice were protected against the development of diaphragm contractile weakness during mechanical ventilation. CONCLUSIONS These findings show that diaphragm muscle fibers of critically ill patients display atrophy and severe contractile weakness, and in the diaphragm of critically ill patients the ubiquitin-proteasome pathway is activated. This study provides rationale for the development of treatment strategies that target the contractility of diaphragm fibers to facilitate weaning.
American Journal of Physiology-lung Cellular and Molecular Physiology | 2008
Hieronymus W. H. van Hees; Yi Ping Li; Coen A.C. Ottenheijm; Bingwen Jin; Cindy J. C. Pigmans; Marianne Linkels; P. N. Richard Dekhuijzen; Leo M. A. Heunks
In congestive heart failure (CHF), diaphragm weakness is known to occur and is associated with myosin loss and activation of the ubiquitin-proteasome pathway. The effect of modulating proteasome activity on myosin loss and diaphragm function is unknown. The present study investigated the effect of in vivo proteasome inhibition on myosin loss and diaphragm function in CHF rats. Coronary artery ligation was used as an animal model for CHF. Sham-operated rats served as controls. Animals were treated with the proteasome inhibitor bortezomib (intravenously) or received saline (0.9%) injections. Force generating capacity, cross-bridge cycling kinetics, and myosin content were measured in diaphragm single fibers. Proteasome activity, caspase-3 activity, and MuRF-1 and MAFbx mRNA levels were determined in diaphragm homogenates. Proteasome activities in the diaphragm were significantly reduced by bortezomib. Bortezomib treatment significantly improved diaphragm single fiber force generating capacity (approximately 30-40%) and cross-bridge cycling kinetics (approximately 20%) in CHF. Myosin content was approximately 30% higher in diaphragm fibers from bortezomib-treated CHF rats than saline. Caspase-3 activity was decreased in diaphragm homogenates from bortezomib-treated rats. CHF increased MuRF-1 and MAFbx mRNA expression in the diaphragm, and bortezomib treatment diminished this rise. The present study demonstrates that treatment with a clinically used proteasome inhibitor improves diaphragm function by restoring myosin content in CHF.
American Journal of Respiratory and Critical Care Medicine | 2011
Frances S. de Man; Hieronymus W. H. van Hees; M. Louis Handoko; Hans W.M. Niessen; Ingrid Schalij; Marc Humbert; Peter Dorfmüller; Olaf Mercier; Harm-Jan Bogaard; Piet E. Postmus; Nico Westerhof; Ger J.M. Stienen; Willem J. van der Laarse; Anton Vonk-Noordegraaf; Coen A.C. Ottenheijm
RATIONALE Recently it was suggested that patients with pulmonary hypertension (PH) suffer from inspiratory muscle dysfunction. However, the nature of inspiratory muscle weakness in PH remains unclear. OBJECTIVES To assess whether alterations in contractile performance and in morphology of the diaphragm underlie inspiratory muscle weakness in PH. METHODS PH was induced in Wistar rats by a single injection of monocrotaline (60 mg/kg). Diaphragm (PH n = 8; controls n = 7) and extensor digitorum longus (PH n = 5; controls n = 7) muscles were excised for determination of in vitro contractile properties and cross-sectional area (CSA) of the muscle fibers. In addition, important determinants of protein synthesis and degradation were determined. Finally, muscle fiber CSA was determined in diaphragm and quadriceps of patients with PH, and the contractile performance of single fibers of the diaphragm. MEASUREMENTS AND MAIN RESULTS In rats with PH, twitch and maximal tetanic force generation of diaphragm strips were significantly lower, and the force-frequency relation was shifted to the right (i.e., impaired relative force generation) compared with control subjects. Diaphragm fiber CSA was significantly smaller in rats with PH compared with controls, and was associated with increased expression of E3-ligases MAFbx and MuRF-1. No significant differences in contractility and morphology of extensor digitorum longus muscle fibers were found between rats with PH and controls. In line with the rat data, studies on patients with PH revealed significantly reduced CSA and impaired contractility of diaphragm muscle fibers compared with control subjects, with no changes in quadriceps muscle. CONCLUSIONS PH induces selective diaphragm muscle fiber weakness and atrophy.
Critical Care | 2011
Hieronymus W. H. van Hees; Willem-Jan M. Schellekens; M Linkels; Floris Leenders; Jan Zoll; Rogier Donders; P. N. Richard Dekhuijzen; Johannes G. van der Hoeven; L.M.A. Heunks
IntroductionICU-acquired muscle weakness commonly occurs in patients with septic shock and is associated with poor outcome. Although atrophy is known to be involved, it is unclear whether ligands in plasma from these patients are responsible for initiating degradation of muscle proteins. The aim of the present study was to investigate if plasma from septic shock patients induces skeletal muscle atrophy and to examine the time course of plasma-induced muscle atrophy during ICU stay.MethodsPlasma was derived from septic shock patients within 24 hours after hospital admission (n = 21) and healthy controls (n = 12). From nine patients with septic shock plasma was additionally derived at two, five and seven days after ICU admission. These plasma samples were added to skeletal myotubes, cultured from murine myoblasts. After incubation for 24 hours, myotubes were harvested and analyzed on myosin content, mRNA expression of E3-ligase and Nuclear Factor Kappa B (NFκB) activity. Plasma samples were analyzed on cytokine concentrations.ResultsMyosin content was approximately 25% lower in myotubes exposed to plasma from septic shock patients than in myotubes exposed to plasma from controls (P < 0.01). Furthermore, patient plasma increased expression of E3-ligases Muscle RING Finger protein-1 (MuRF-1) and Muscle Atrophy F-box protein (MAFbx) (P < 0.01), enhanced NFκB activity (P < 0.05) and elevated levels of ubiquitinated myosin in myotubes. Myosin loss was significantly associated with elevated plasma levels of interleukin (IL)-6 in septic shock patients (P < 0.001). Addition of antiIL-6 to septic shock plasma diminished the loss of myosin in exposed myotubes by approximately 25% (P < 0.05). Patient plasma obtained later during ICU stay did not significantly reduce myosin content compared to controls.ConclusionsPlasma from patients with septic shock induces loss of myosin and activates key regulators of proteolysis in skeletal myotubes. IL-6 is an important player in sepsis-induced muscle atrophy in this model. The potential to induce atrophy is strongest in plasma obtained during the early phase of human sepsis.
Anesthesiology | 2012
Willem-Jan M. Schellekens; Hieronymus W. H. van Hees; Michiel Vaneker; Marianne Linkels; P. N. Richard Dekhuijzen; Gert Jan Scheffer; Johannes G. van der Hoeven; Leo M. A. Heunks
Background: Mechanical ventilation induces diaphragm muscle atrophy, which plays a key role in difficult weaning from mechanical ventilation. The signaling pathways involved in ventilator-induced diaphragm atrophy are poorly understood. The current study investigated the role of Toll-like receptor 4 signaling in the development of ventilator-induced diaphragm atrophy. Methods: Unventilated animals were selected for control: wild-type (n = 6) and Toll-like receptor 4 deficient mice (n = 6). Mechanical ventilation (8 h): wild-type (n = 8) and Toll-like receptor 4 deficient (n = 7) mice. Myosin heavy chain content, proinflammatory cytokines, proteolytic activity of the ubiquitin-proteasome pathway, caspase-3 activity, and autophagy were measured in the diaphragm. Results: Mechanical ventilation reduced myosin content by approximately 50% in diaphragms of wild-type mice (P less than 0.05). In contrast, ventilation of Toll-like receptor 4 deficient mice did not significantly affect diaphragm myosin content. Likewise, mechanical ventilation significantly increased interleukin-6 and keratinocyte-derived chemokine in the diaphragm of wild-type mice, but not in ventilated Toll-like receptor 4 deficient mice. Mechanical ventilation increased diaphragmatic muscle atrophy factor box transcription in both wild-type and Toll-like receptor 4 deficient mice. Other components of the ubiquitin-proteasome pathway and caspase-3 activity were not affected by ventilation of either wild-type mice or Toll-like receptor 4 deficient mice. Mechanical ventilation induced autophagy in diaphragms of ventilated wild-type mice, but not Toll-like receptor 4 deficient mice. Conclusion: Toll-like receptor 4 signaling plays an important role in the development of ventilator-induced diaphragm atrophy, most likely through increased expression of cytokines and activation of lysosomal autophagy.
American Journal of Respiratory and Critical Care Medicine | 2014
Pleuni E. Hooijman; Albertus Beishuizen; Monique C. de Waard; Frances S. de Man; J. W. Vermeijden; Pascal Steenvoorde; R. Arthur Bouwman; Wies Lommen; Hieronymus W. H. van Hees; Leo M. A. Heunks; Chris Dickhoff; Donald L. van der Peet; Armand R. J. Girbes; Jeff R. Jasper; Fady Malik; Ger J.M. Stienen; Koen J. Hartemink; Marinus A. Paul; Coen A.C. Ottenheijm
To the Editor: Diaphragm weakness in the intensive care unit (ICU) plays an important role in difficult weaning from mechanical ventilation. Diaphragm strength in mechanically ventilated (MV) critically ill patients has been assessed indirectly using phrenic nerve stimulation, which demonstrated that the pressure-generating capacity of the diaphragm was reduced in these patients (1–3). However, this technique cannot distinguish between impaired phrenic nerve function, abnormal neuromuscular transmission, and intrinsic abnormalities in the diaphragm muscle itself. Consequently, it is unknown whether intrinsic contractile weakness of diaphragm muscle fibers occurs in MV critically ill patients. If so, targeted treatment strategies that enhance contractility may improve the success of weaning. Such treatment strategies may include the administration of a novel class of small-molecule drugs, named fast skeletal troponin activators, which improve the contractile strength of skeletal muscle fibers (4). In this study, we obtained diaphragm biopsy specimens from critically ill patients (n = 10; MV for 28–603 h) undergoing laparotomy or thoracotomy, and compared them with control patients undergoing elective lung surgery (n = 10; MV 1–2 h, see Table E1 in the online supplement). The size and the contractile performance of isolated diaphragm muscle fibers were determined. In addition, we tested the ability of the fast skeletal troponin activator, CK-2066260, to improve contractile strength. Diaphragm fiber cross-sectional area (CSA) was determined by means of immunohistochemical analyses with myosin heavy chain antibodies performed on cryosections of the biopsy specimens (5, 6). Figure 1A demonstrates atrophy of slow- and fast-twitch diaphragm fibers in critically ill patients (CSA slow-twitch fibers: control patients, 3,284 ± 793 μm2 vs. critically ill patients, 2,328 ± 763 μm2, P = 0.004; fast-twitch fibers: control patients, 2,766 ± 606 μm2 vs. critically ill patients, 1,819 ± 527 μm2, P < 0.0001). Figure 1. (A) Severe diaphragm muscle fiber atrophy in mechanically ventilated (MV) critically ill patients. Typical examples of serial diaphragm cross-sections stained with antibodies against slow-twitch myosin heavy chain (green). Wheat germ agglutinin (WGA) ... We measured the contractile performance of permeabilized single diaphragm fibers isolated from the biopsy specimens. Fibers were mounted between a force transducer and a length motor, and exposed to activating calcium solutions. Maximal contractile strength was markedly lower in critically ill patients (absolute force slow-twitch fibers: control patients, 0.44 ± 0.16 mN vs. critically ill patients, 0.19 ± 0·07 mN, P < 0.0001; fast-twitch fibers: control patients, 0.49 ± 0.21 mN vs. critically ill patients, 0.24 ± 0.09 mN, P = 0.0002; Figure 1B). After normalization of force to the CSA of these fibers (i.e., specific force), a deficit remained in diaphragm fibers of critically ill patients (see Figure E1). This suggests that, in these critically ill patients, there is not only a loss of contractile proteins, but also dysfunction of the remaining ones. In addition, we measured the sensitivity of force to calcium. The negative logarithm of the calcium concentration needed to obtain 50% of maximal force (pCa50) was unaffected in slow-twitch fibers (control patients, 5.64 ± 0.03 vs. critically ill patients, 5.61 ± 0.08, P = 0.30), whereas, in fast-twitch fibers, the pCa50 was significantly lower in critically ill patients (control patients, 5.76 ± 0.07 vs. critically ill patients, 5.70 ± 0.06, P = 0.036) (Figure 1B). Thus, fast-twitch diaphragm fibers from critically ill patients not only have reduced maximal force, but also require more calcium to generate force. We exposed diaphragm fibers of a representative subset of control patients (nos. I, IV, VI) and critically ill patients (nos. 1, 3, 4, 5) to the fast skeletal troponin activator, CK-2066260, which improves the sensitivity of the calcium sensor in the muscle sarcomere. Compared with vehicle, 5 μM of CK-2066260 significantly increased the calcium sensitivity of diaphragm fibers both in control patients (pCa50: 5.75 ± 0.04 vs. 6.18 ± 0.1, respectively; P < 0.001) and in critically ill patients (5.70 ± 0.07 vs. 6.00 ± 0.13, respectively; P < 0.01) (Figure 1C). Importantly, at physiological calcium concentrations, CK-2066260 restored the contractile force of fast-twitch diaphragm fibers of critically ill patients back to levels observed in untreated fibers from control patients (force at pCa 5.8: untreated control patients, 0.22 ± 0.05 vs. treated critically ill patients, 0.22 ± 0.07 mN; P = 0.954). See the online supplement for details. The current study is the first to show that atrophy and contractile weakness of diaphragm muscle fibers develop in a clinically relevant group of MV critically ill patients. Interestingly, the reduction in the contractile force of diaphragm fibers of these critically ill patients is comparable to the reduction in diaphragm strength estimated previously by phrenic nerve pacing (1, 2), indicating that the reduction in diaphragm strength in these patients largely results from muscle fiber weakness. To date, no drug is approved to improve respiratory muscle function in MV critically ill patients. We made a step toward such a strategy by testing the ability of the fast skeletal troponin activator, CK-2066260, to restore diaphragm fiber strength. We observed that, upon exposure to CK-2066260, fast-twitch diaphragm fibers from critically ill patients regained strength at calcium concentrations that reflect activation during daily live activities to levels found in untreated fibers from control patients (Figure 1C). Because approximately 50% of fibers and total fiber area in the human diaphragm consists of fast-twitch fibers (Figure E3), fast skeletal troponin activators might significantly improve in vivo diaphragm strength. The potential of fast troponin activators is further strengthened by the notion that these drugs do not affect cardiac function (4), which would be an undesirable side effect in critically ill patients. The analog of CK-2066260, tirasemtiv (formerly CK-2017357), is currently under study in patients with amyotrophic lateral sclerosis (clinical trial no. NCT01709149). What causes weakness of diaphragm muscle fibers in critically ill patients? It seems plausible that the observed diaphragm weakness was acquired during ICU stay, as we used strict exclusion criteria to rule out that our study patients had pre-existing diaphragm weakness. Also, during their stay in the ICU, patients received nutrition according to an optimized nutrition algorithm (7). A commonly suggested concept is that mechanical ventilation per se rapidly induces weakness and atrophy of muscle fibers due to contractile inactivity of the diaphragm (8–12). The critically ill patients we studied received MV for 28–603 hours before biopsy, a time frame that was associated with significant reductions in the CSA of diaphragm fibers in braindead organ donors (8, 13). Thus, the diaphragm muscle fiber atrophy and weakness that we observed may, at least partly, be explained by mechanical ventilation per se. Other ICU-related phenomena that could contribute to diaphragm muscle weakness include underlying disease, such as sepsis (14, 15). Clearly, to elucidate the main factors that contribute to the observed diaphragm muscle fiber weakness requires studies with larger cohorts of various patient groups.
Critical Care Medicine | 2012
Anouk Agten; Karen Maes; Debby Thomas; Nele Cielen; Hieronymus W. H. van Hees; Richard Dekhuijzen; Marc Decramer; Ghislaine Gayan-Ramirez
Objective: Controlled mechanical ventilation leads to diaphragmatic contractile dysfunction and atrophy. Since proteolysis is enhanced in the diaphragm during controlled mechanical ventilation, we examined whether the administration of a proteasome inhibitor, bortezomib, would have a protective effect against ventilator-induced diaphragm dysfunction. Design: Randomized, controlled experiment. Settings: Basic science animal laboratory. Interventions: Anesthetized rats were submitted for 24 hrs to controlled mechanical ventilation while receiving 0.05 mg/kg bortezomib or saline. Control rats were acutely anesthetized. Measurements and Main Results: After 24 hrs, diaphragm force production was significantly lower in mechanically ventilated animals receiving an injection of saline compared to control animals (−36%, p < .001). Importantly, administration of bortezomib improved the diaphragmatic force compared to mechanically ventilated animals receiving an injection of saline (+15%, p < .01), but force did not return to control levels. Compared to control animals, diaphragm cross-sectional area of the type IIx/b fibers was significantly decreased by 28% in mechanically ventilated animals receiving an injection of saline (p < .01) and by 16% in mechanically ventilated animals receiving an injection of bortezomib (p < .05). Diaphragmatic calpain activity was significantly increased in mechanically ventilated animals receiving an injection of saline (+52%, p < .05) and in mechanically ventilated animals receiving an injection of bortezomib (+36%, p < .05). Caspase-3 activity was increased after controlled mechanical ventilation with saline by 55% (p < .05), while it remained similar to control animals in mechanically ventilated animals receiving an injection of bortezomib. Diaphragm 20S proteasome activity was slightly increased in both ventilated groups, and the amount of ubiquitinated proteins was significantly and similarly enhanced in mechanically ventilated animals receiving an injection of saline and mechanically ventilated animals receiving an injection of bortezomib. Conclusions: These data show that the administration of bortezomib partially protects the diaphragm from controlled mechanical ventilation–induced diaphragm contractile dysfunction without preventing atrophy. The fact that calpain activity was still increased after bortezomib treatment may explain the persistence of atrophy. Part of bortezomib effects might have been due to its ability to inhibit caspase-3 in this model.
Anesthesiology | 2009
Michiel Vaneker; Leo M. A. Heunks; Leo A. B. Joosten; Hieronymus W. H. van Hees; Dirk G. Snijdelaar; Feico J. Halbertsma; Jan van Egmond; Mihai G. Netea; Johannes G. van der Hoeven; Gert Jan Scheffer
Background:Mechanical ventilation (MV) can induce lung injury. Proinflammatory cytokines have been shown to play an important role in the development of ventilator-induced lung injury. Previously, the authors have shown a role for Toll-like receptor 4 signaling. The current study aims to investigate the role of Toll/interleukin-1 receptor domain-containing adapter-inducing interferon-&bgr; (TRIF), a protein downstream of Toll-like receptors, in the development of the inflammatory response after MV in healthy mice. Methods:Wild-type C57BL6 and TRIF mutant mice were mechanically ventilated for 4 h. Lung tissue and plasma was used to investigate changes in cytokine profile, leukocyte influx, and nuclear factor-&kgr;B activity. In addition, experiments were performed to assess the role of TRIF in changes in cardiopulmonary physiology after MV. Results:MV significantly increased messenger RNA expression of interleukin (IL)-1&bgr; in wild-type mice, but not in TRIF mutant mice. In lung homogenates, MV increased levels of IL-1&agr;, IL-1&bgr;, and keratinocyte-derived chemokine in wild-type mice. In contrast, in TRIF mutant mice, only a minor increase in IL-1&bgr; and keratinocyte-derived chemokine was found after MV. Nuclear factor-&kgr;B activity after MV was significantly lower in TRIF mutant mice compared with wild-type mice. In plasma, MV increased levels of IL-6 and keratinocyte-derived chemokine. In TRIF mutant mice, no increase of IL-6 was found after MV, and the increase in keratinocyte-derived chemokine appeared less pronounced. TRIF deletion did not affect cardiopulmonary physiology after MV. Conclusions:The current study supports a prominent role for TRIF in the development of the pulmonary and systemic inflammatory response after MV.
American Journal of Physiology-lung Cellular and Molecular Physiology | 2011
Hieronymus W. H. van Hees; Coen A.C. Ottenheijm; Leo Ennen; Marianne Linkels; Richard Dekhuijzen; Leo M. A. Heunks
Diaphragm muscle weakness in patients with chronic obstructive pulmonary disease (COPD) is associated with increased morbidity and mortality. Recent studies indicate that increased contractile protein degradation by the proteasome contributes to diaphragm weakness in patients with COPD. The aim of the present study was to investigate the effect of proteasome inhibition on diaphragm function and contractile protein concentration in an animal model for COPD. Elastase-induced emphysema in hamsters was used as an animal model for COPD; normal hamsters served as controls. Animals were either treated with the proteasome inhibitor Bortezomib (iv) or its vehicle saline. Nine months after induction of emphysema, specific force-generating capacity of diaphragm bundles was measured. Proteolytic activity of the proteasome was assayed spectrofluorometrically. Protein concentrations of proteasome, myosin, and actin were measured by means of Western blotting. Proteasome activity and concentration were significantly higher in the diaphragm of emphysematous hamsters than in normal hamsters. Bortezomib treatment reduced proteasome activity in the diaphragm of emphysematous and normal hamsters. Specific force-generating capacity and myosin concentration of the diaphragm were reduced by ~25% in emphysematous hamsters compared with normal hamsters. Bortezomib treatment of emphysematous hamsters significantly increased diaphragm-specific force-generating capacity and completely restored myosin concentration. Actin concentration was not affected by emphysema, nor by bortezomib treatment. We conclude that treatment with a proteasome inhibitor improves contractile function of the diaphragm in emphysematous hamsters through restoration of myosin concentration. These findings implicate that the proteasome is a potential target of pharmacological intervention on diaphragm weakness in COPD.
American Journal of Physiology-lung Cellular and Molecular Physiology | 2011
Coen A.C. Ottenheijm; Hieronymus W. H. van Hees; Leo M. A. Heunks; Henk Granzier
The diaphragm, the main muscle of inspiration, is constantly subjected to mechanical loading. One of the very few occasions during which diaphragm loading is arrested is during controlled mechanical ventilation in the intensive care unit. Recent animal studies indicate that the diaphragm is extremely sensitive to unloading, causing rapid muscle fiber atrophy: unloading-induced diaphragm atrophy and the concomitant diaphragm weakness has been suggested to contribute to the difficulties in weaning patients from ventilatory support. Little is known about the molecular triggers that initiate the rapid unloading atrophy of the diaphragm, although proteolytic pathways and oxidative signaling have been shown to be involved. Mechanical stress is known to play an important role in the maintenance of muscle mass. Within the muscles sarcomere titin is considered to play an important role in the stress-response machinery. Titin is the largest protein known to date and acts as a mechanosensor that regulates muscle protein expression in a sarcomere strain-dependent fashion. Thus, titin is an attractive candidate for sensing the sudden mechanical arrest of the diaphragm when patients are mechanically ventilated, leading to changes in muscle protein expression. Here, we provide a novel perspective on how titin, and its biomechanical sensing and signaling, might be involved in the development of mechanical unloading-induced diaphragm weakness.